PHO - 52% vekst i USA!
Oslo, Norway, 14 May 2019:
Photocure ASA (OSE:PHO), today reported a revenue growth of 52% in local
currency for the U.S. market in the first quarter of 2019, contributing to
Hexvix/Cysview revenues of NOK 51.2 million (Q1 2018: NOK 40.7) and a recurring
EBITDA of NOK -1.5 million (NOK -4.0 million). The company continues to receive
strong endorsement for the use of Blue Light Cystoscopy (BLC) with Cysview and
reiterates the significant revenue growth and profit opportunities in the U.S.
market.
"We are off to a strong start in 2019, continuing the momentum begun in 2018 by
posting another record quarter of results. In particular, the US growth
trajectory continues with an increase of 52% in USD. We are still very early in
the launch phase of Flex in the US with tremendous potential for long term
sustained growth. Our direct efforts in the Nordic countries continue to produce
strong single digit growth as expected in this mature region of the world. And
partnered sales have begun to show improvement with increased expectations and
efforts," says Daniel Schneider, President & Chief Executive Officer of
Photocure.
Photocure ASA (OSE:PHO), today reported a revenue growth of 52% in local
currency for the U.S. market in the first quarter of 2019, contributing to
Hexvix/Cysview revenues of NOK 51.2 million (Q1 2018: NOK 40.7) and a recurring
EBITDA of NOK -1.5 million (NOK -4.0 million). The company continues to receive
strong endorsement for the use of Blue Light Cystoscopy (BLC) with Cysview and
reiterates the significant revenue growth and profit opportunities in the U.S.
market.
"We are off to a strong start in 2019, continuing the momentum begun in 2018 by
posting another record quarter of results. In particular, the US growth
trajectory continues with an increase of 52% in USD. We are still very early in
the launch phase of Flex in the US with tremendous potential for long term
sustained growth. Our direct efforts in the Nordic countries continue to produce
strong single digit growth as expected in this mature region of the world. And
partnered sales have begun to show improvement with increased expectations and
efforts," says Daniel Schneider, President & Chief Executive Officer of
Photocure.
Redigert 21.01.2021 kl 06:19
Du må logge inn for å svare
Helme5
19.05.2019 kl 21:56
1649
SomSa - laver du grin eller mener du det virkelig....
4 nuværende sælgere (de bedste) oplærer et antal (formodentlig de nye/nyere) - hvordan kan du få det til 40-4 = 36, dem der oplæres er vel ej heller i markedet så her regner du helt forkert... De 40 er inklusiv de nye, har du slet ikke set Q1.?
Der er ikke forsvundet 15 mill af kontanterne i regnskabet, det fremgår jo tydeligt hvorfor likviderne blev formindsket, se evt omkring leverandørgæld, som jeg lige husker det..!!
Jeg troede du kunne tal, du har tidligere vist gode egenskaber også der, men noget måtte være sket, siden du er blevet noget forvandlet i din retorik..
Emnisjon - den tror jeg ikke på, tværtimod - men intet er sikkert, så meget vil jeg give dig.
4 nuværende sælgere (de bedste) oplærer et antal (formodentlig de nye/nyere) - hvordan kan du få det til 40-4 = 36, dem der oplæres er vel ej heller i markedet så her regner du helt forkert... De 40 er inklusiv de nye, har du slet ikke set Q1.?
Der er ikke forsvundet 15 mill af kontanterne i regnskabet, det fremgår jo tydeligt hvorfor likviderne blev formindsket, se evt omkring leverandørgæld, som jeg lige husker det..!!
Jeg troede du kunne tal, du har tidligere vist gode egenskaber også der, men noget måtte være sket, siden du er blevet noget forvandlet i din retorik..
Emnisjon - den tror jeg ikke på, tværtimod - men intet er sikkert, så meget vil jeg give dig.
Redigert 21.01.2021 kl 04:11
Du må logge inn for å svare
SomSa
19.05.2019 kl 21:57
1649
Fra 29. November 2018 leser vi at det var 40 ansatte i USA og 30 i Norge eller totalt 70, samtidig sa Daiel på Pdcast at de hadde omorganisert og 3-4 skulle jobbe på kontor og resten skulle drive med salg. Noen på forumet hadde hevdet at det ble ansatt 3 nye selgere i 1Q 2019.
"70 EMPLOYEES Of which 40 in US"
side 3:
https://photocure.com/globalassets/investor-relations/presentations/2018-pres/pho-nals-20181129.pdf
Det ser sånn ut at ting ikke har fungert og de var nødt til å ommøbler igjen, muligens si opp flere og ansatte noen andre.....
Re-focused Existing Headcount
• 27 Sales Reps – Key Hospitals
• 4 Key Account Managers – LUGPA & IDNs (Integrated DeliveryNetworks)
• 4 Regional Managers
Side 21
https://photocure.com/globalassets/investor-relations/presentations/2019-pres/pho-q1-2019-pres-vf.pdfSide 21
Ikke bry deg om en vekst på 75% i 4Q 2018 i forhold til 1Q 2017. Det eksisterte ikke refusjonsordning i 4Q 2017 og det kom på plass i 1Q 2018. Bare de eksisterende skopene i 4Q 2017 burde generere 200%-300% mer inntekter uten nye skop.........................
Redigert 21.01.2021 kl 04:11
Du må logge inn for å svare
Somsa, we all know that the reason for the low frequency of use is the ultra complex refusjons ordning.
The poor urologists need a degree in problem solving just to understand how it works.
Make it simple and you increase the frequency of use.
The poor urologists need a degree in problem solving just to understand how it works.
Make it simple and you increase the frequency of use.
Redigert 21.01.2021 kl 04:11
Du må logge inn for å svare
focuss
19.05.2019 kl 22:39
1592
Sug litt på denne
Acceptance, by key institutions; key to oncology products is the adoption of key reference centers. Now, with expanded US sales team, we are aiming to get 100% adoption by these most reputable institutions in the United States. These reference centers set the standard for patient care.
Acceptance, by key institutions; key to oncology products is the adoption of key reference centers. Now, with expanded US sales team, we are aiming to get 100% adoption by these most reputable institutions in the United States. These reference centers set the standard for patient care.
Redigert 21.01.2021 kl 04:11
Du må logge inn for å svare
focuss
19.05.2019 kl 22:49
1577
Schneider fra linken til Bente
"With focused execution, we'll achieve our ambition to make Cysview the standard of care in bladder cancer."
Uttalelsene til Schneider viser at Schneider er ingen kylling.
"With focused execution, we'll achieve our ambition to make Cysview the standard of care in bladder cancer."
Uttalelsene til Schneider viser at Schneider er ingen kylling.
Redigert 21.01.2021 kl 04:11
Du må logge inn for å svare